In the USA, two different classes of bone targeting agents (BTAs), bisphosphonates and the receptor activator of nuclear factor-kappa β ligand (RANKL) inhibitor denosumab, are indicated for the prevention of SREs in patients with bone metastases from solid tumors, including BC patients with BM. This evidence concerns the gene TNFSF11 and breast cancer.